CA
NZ
UK
AU
IND
US
…
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral therapies that target G protein‑coupled receptors for rare endocrine diseases, with a pipeline led by candidates in development for acromegaly and other hormonal disorders. Long-term growth may be driven by clinical progression of late-stage programs, potential regulatory approvals and commercial launches, and expansion into additional indications or partnerships, which could support meaningful patient and revenue reach if successful.
The principal investment risks are high clinical and regulatory uncertainty, reliance on a small number of programs, potential need for additional financing and competitive pressures from established therapies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -163.92M | -107.64M | -73.81M | -50.42M | -27.11M |
| Net income | -159.95M | -106.72M | -72.86M | -49.53M | -27.11M |
| Selling general administrative | 42.39M | 24.52M | 18.03M | 13.52M | 6.66M |
| Gross profit | 4.74M | 1.08M | 0.07M | 1.19M | 2.43M |
| Reconciled depreciation | 0.98M | 0.92M | 0.95M | 0.89M | 0.47M |
| Ebit | -168.87M | -108.62M | -75.90M | -54.72M | -29.18M |
| Ebitda | -167.88M | -107.70M | -74.95M | -53.83M | -28.71M |
| Depreciation and amortization | 0.98M | 0.92M | 0.95M | 0.89M | 0.47M |
| Non operating income net other | - | - | 1.14M | 3.41M | 1.59M |
| Operating income | -167.88M | -107.70M | -74.95M | -53.83M | -28.71M |
| Other operating expenses | 172.62M | 108.78M | 74.95M | 53.83M | 28.71M |
| Interest expense | 4.32M | 0.06M | 0.99M | 0.00M | 0.00M |
| Interest income | 4.32M | 0.16M | 0.99M | 3.46M | 1.75M |
| Net interest income | 4.32M | 0.16M | 0.99M | 3.46M | 1.75M |
| Income tax expense | -3.96M | -0.92M | -0.95M | -0.89M | 1.59M |
| Total revenue | 4.74M | 1.08M | 0.07M | 1.19M | 2.43M |
| Total operating expenses | 172.62M | 108.78M | 74.95M | 53.83M | 28.71M |
| Cost of revenue | - | - | - | 41.51M | 24.48M |
| Total other income expense net | 3.96M | 0.06M | 1.14M | 3.41M | 1.59M |
| Net income from continuing ops | -163.92M | -107.64M | -73.81M | -50.42M | -27.11M |
| Net income applicable to common shares | -163.92M | -107.64M | -73.81M | -50.42M | -27.11M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 635.35M | 352.18M | 351.01M | 183.44M | 130.38M |
| Other current assets | 6.25M | 8.33M | 0.91M | 6.61M | 4.95M |
| Total liab | 96.25M | 35.85M | 19.07M | 14.53M | 13.24M |
| Total stockholder equity | 539.11M | -439.17M | -275.25M | -167.61M | -93.80M |
| Deferred long term liab | - | - | - | 0.02M | 0.05M |
| Other current liab | 31.16M | 18.60M | 7.53M | 4.90M | 2.84M |
| Common stock | 1191.83M | 759.43M | 607.58M | 336.51M | 210.79M |
| Capital stock | 1191.83M | 759.43M | 607.58M | 336.51M | 210.79M |
| Retained earnings | -653.70M | -439.17M | -275.25M | -167.61M | -93.80M |
| Other liab | - | 6.10M | 0.00M | 0.02M | 0.05M |
| Other assets | 0.00M | 2.01M | 0.57M | 2.77M | 0.58M |
| Cash | 54.90M | 32.67M | 200.69M | 93.09M | 40.33M |
| Total current liabilities | 43.94M | 27.72M | 15.99M | 10.49M | 8.34M |
| Current deferred revenue | 2.06M | 2.24M | - | - | - |
| Net debt | -3.17M | -30.65M | -197.62M | -89.07M | -35.48M |
| Short term debt | 4.17M | - | - | 4.01M | - |
| Short long term debt total | 51.73M | 2.02M | 3.07M | 4.01M | 4.85M |
| Other stockholder equity | - | -755.50M | -607.20M | -336.53M | -210.94M |
| Property plant equipment | - | 4.99M | 4.72M | 5.41M | 6.46M |
| Total current assets | 574.15M | 345.18M | 344.72M | 177.49M | 123.34M |
| Long term investments | 0.47M | 0.00M | 1.01M | - | - |
| Net tangible assets | - | 316.33M | 331.94M | 168.92M | 117.14M |
| Short term investments | 503.66M | 301.75M | 133.01M | 77.79M | 78.07M |
| Net receivables | 9.35M | 2.42M | 2.03M | 1.83M | 1.38M |
| Inventory | - | - | 8.07M | -1.83M | -1.38M |
| Accounts payable | 6.55M | 6.88M | 8.47M | 5.59M | 5.50M |
| Accumulated other comprehensive income | 0.98M | -3.93M | -0.38M | 0.03M | 0.15M |
| Common stock total equity | - | - | - | 336.51M | 210.79M |
| Retained earnings total equity | - | - | - | -167.61M | -93.80M |
| Non currrent assets other | 2.00M | 2.01M | 0.57M | 0.54M | 0.58M |
| Non current assets total | 61.20M | 6.99M | 6.29M | 5.95M | 7.04M |
| Capital lease obligations | 51.73M | 2.02M | 3.07M | 4.01M | 4.85M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -173.98M | -56.48M | 0.22M | 42.16M | -118.40M |
| Change to liabilities | 19.34M | 6.29M | 2.72M | 0.70M | 7.36M |
| Total cashflows from investing activities | -173.98M | -56.48M | 0.22M | 41.67M | -119.46M |
| Total cash from financing activities | 121.96M | 252.68M | 114.57M | 0.07M | 170.20M |
| Change to operating activities | -0.72M | -5.20M | -2.35M | -2.83M | -2.06M |
| Net income | -163.92M | -107.64M | -73.81M | -50.42M | -27.11M |
| Change in cash | -167.22M | 107.61M | 52.76M | -4.65M | 31.28M |
| Begin period cash flow | 201.19M | 93.59M | 40.83M | 45.47M | 14.19M |
| End period cash flow | 33.97M | 201.19M | 93.59M | 40.83M | 45.47M |
| Total cash from operating activities | -115.20M | -88.59M | -62.03M | -46.38M | -19.46M |
| Issuance of capital stock | 117.24M | 249.54M | 114.28M | 0.00M | 169.75M |
| Depreciation | 0.98M | 0.92M | 0.95M | 0.89M | 0.47M |
| Other cashflows from investing activities | - | - | - | 42.16M | -118.40M |
| Change to account receivables | 10.99M | - | - | - | - |
| Sale purchase of stock | - | 0.00M | 114.57M | -0.06M | 170.20M |
| Other cashflows from financing activities | 4.72M | 3.14M | 0.29M | 0.13M | 63.73M |
| Change to netincome | 29.12M | 17.04M | 10.46M | 6.29M | 1.89M |
| Capital expenditures | 1.66M | 0.44M | 0.19M | 0.49M | 1.06M |
| Cash flows other operating | - | - | -2.07M | -2.60M | -2.06M |
| Cash and cash equivalents changes | - | - | 52.76M | -4.65M | 31.28M |
| Change in working capital | 18.61M | 1.10M | 0.38M | -2.13M | 5.30M |
| Stock based compensation | 28.27M | 17.35M | 10.43M | 6.29M | 2.32M |
| Other non cash items | 0.85M | -0.74M | 0.26M | 0.22M | -0.43M |
| Free cash flow | -116.86M | -89.02M | -62.21M | -46.87M | -20.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.08 0.20% |
39.13 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.65 0.33% |
807.67 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. R. Scott Struthers Ph.D. | Founder, Pres, CEO & Director | 1962 |
| Mr. Jeff E. Knight | Chief Operating Officer | 1971 |
| Dr. Stephen F. Betz Ph.D. | Founder & Chief Scientific Officer | 1966 |
| Mr. Marc J. C. Wilson | Chief Financial Officer | 1979 |
| Ms. Garlan Adams | Gen. Counsel & Corp. Sec. | NA |
| Ms. Adriana Cabre M.B.A. | Chief HR Officer | NA |
| Dr. Alan S. Krasner M.D. | Chief Medical Officer | 1963 |
| Mr. Kevin Capps | Head of Intellectual Property | NA |
| Mr. James Hassard | Chief Commercial Officer | 1966 |
| Mr. Chris Robillard M.B.A. | Chief Bus. Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...